Answers are grounded in this paper and cite their sources.
• Distinct entity – By using histology, immunohistochemistry, whole-genome sequencing, and a reanalysis of a 75-case public dataset, we herein demonstrated that LCNEC-P forms a cohesive biological group with SCLC-P that is clearly separate from other LCNEC/SCLC subtypes. • Diagnostic impact – We confirmed POU2F3 immunostaining as a practical marker and delineated pitfalls, such as basaloid squamous cell carcinoma with POU2F3 positivity, offering a concrete diagnostic algorithm. • Therapeutic insight – We observed a relatively high frequency of FGFR1 amplification (60%) in LCNEC-P, indicating a possible therapeutic relevance in this subset. • Clinical relevance – NEC-P has significantly poorer 5-year overall survival and is closely associated with RB1 inactivation, indicating the need for tailored management. Large cell neuroendocrine carcinoma (LCNEC) is a neuroendocrine carcinoma (NEC) of the lung that is characterized by its heterogeneous morphology, diverse immunophenotypes, and complex genomic profiles. Among LCNECs, a subset expressing the transcription factor POU2F3 (LCNEC-P) has been suggested to share similarities with small cell lung carcinoma (SCLC)-P, a subtype of SCLC defined by POU2F3 expression. However, the specific characteristics of LCNEC-P have not been fully elucidated. Therefore, the aim of the present study is to clarify the clinicopathological, immunohistochemical, and genetic characteristics of LCNEC-P. Fifty-six LCNEC cases were analyzed, including 12 LCNEC-P and 44 LCNEC-non-P cases. Morphologically, LCNEC-P exhibited significantly lower cytomorphology scores, indicating a resemblance to SCLC. Immunohistochemically, LCNEC-P showed the lower expression of neuroendocrine markers (SYP, CHGA, and INSM1), but the higher expression of C-MYC than LCNEC-non-P. A strong mutually exclusive expression pattern was observed between POU2F3 and ASCL1/NEUROD1. Whole-genome sequencing of 20 cases revealed that LCNEC-P harbored RB1 mutations in 100% of cases, which was significantly higher than in LCNEC-non-P (40%). FGFR1 amplification was observed in 60% of LCNEC-P cases, representing a higher prevalence than previously reported for LCNEC. In addition, LCNEC-P showed a distinct copy number alteration profile, including frequent 20q13 amplification, compared with LCNEC-non-P. These results demonstrate that LCNEC-P represents a distinct subgroup of LCNEC that is characterized by a specific morphological, immunohistochemical, and genetic profile, closely resembling SCLC-P. This study provides insights into the biology of LCNEC-P and supports its classification as a unique entity within LCNEC.
No takes yet. Share an insight, caveat, or question.
Matsuoka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: